{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:04:22Z","timestamp":1785416662377,"version":"3.56.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.05.016","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:57:05Z","timestamp":1779231425000},"page":"992.e1-992.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["High Incidence of Cytomegalovirus Infection in Patients Receiving Standard of Care CD19- or BCMA-Targeted CAR-T Cell Therapies for Hematologic Malignancies"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6376-4495","authenticated-orcid":false,"given":"Tamer","family":"Othman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8291-6546","authenticated-orcid":false,"given":"John H.","family":"Baird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Pak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8683-595X","authenticated-orcid":false,"given":"Yi-Ping","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Shouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Popplewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Aribi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6650-5704","authenticated-orcid":false,"given":"Myo","family":"Htut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joycelynne","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua E.","family":"Budde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1099-0568","authenticated-orcid":false,"given":"Sanjeet S.","family":"Dadwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10299","key":"10.1016\/j.jtct.2026.05.016_bib0001","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"The Lancet"},{"issue":"7","key":"10.1016\/j.jtct.2026.05.016_bib0002","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.016_bib0003","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jtct.2026.05.016_bib0004","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1182\/bloodadvances.2023010624","article-title":"Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry","volume":"7","author":"Lemoine","year":"2023","journal-title":"Blood Advances"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.016_bib0005","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.016_bib0006","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.016_bib0007","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1186\/s12879-019-4545-7","article-title":"Disseminated cytomegalovirus disease after bendamustine: a case report and analysis of circulating B- and T-cell subsets","volume":"19","author":"Cona","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jtct.2026.05.016_bib0008","article-title":"Lymphodepletion \u2013 an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Review. Front Immunol"},{"issue":"9","key":"10.1016\/j.jtct.2026.05.016_bib0009","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.6004\/jnccn.2018.0073","article-title":"Chimeric antigen receptor T-cell therapy","volume":"16","author":"Ogba","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.016_bib0010","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3324\/haematol.2022.281719","article-title":"Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant","volume":"108","author":"Chen","year":"2023","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jtct.2026.05.016_bib0011","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciab1064","article-title":"Impact of letermovir primary cytomegalovirus prophylaxis on 1-year mortality after allogeneic hematopoietic cell transplantation: a retrospective cohort study","volume":"75","author":"Su","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"25","key":"10.1016\/j.jtct.2026.05.016_bib0012","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jtct.2026.05.016_bib0013","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1002\/jmv.27257","article-title":"Severe cytomegalovirus disease with encephalitis after CAR-T cell therapy: A rare but potentially fatal complication","volume":"93","author":"Cousin","year":"2021","journal-title":"J Med Virol"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.016_bib0014","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3390\/curroncol29020044","article-title":"Cytomegalovirus retinitis and retinal detachment following chimeric antigen receptor T cell therapy for relapsed\/refractory multiple myeloma","volume":"29","author":"Zu","year":"2022","journal-title":"Curr Oncol"},{"issue":"10","key":"10.1016\/j.jtct.2026.05.016_bib0015","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41408-021-00563-8","article-title":"Viral infection\/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.016_bib0016","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/cid\/ciad708","article-title":"Cytomegalovirus (CMV) reactivation and CMV-specific cell-mediated immunity after chimeric antigen receptor T-cell therapy","volume":"78","author":"Kampouri","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.016_bib0017","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.cmi.2023.05.010","article-title":"Cytomegalovirus DNAemia in haematological patients undergoing CD19-directed chimeric antigen receptor T-cell therapy: should it be systematically monitored?","volume":"29","author":"Solano de la Asunci\u00f3n","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.016_bib0018","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/ejh.13712","article-title":"Characteristics and recognition of early infections in patients treated with commercial anti-CD19 CAR-T cells","volume":"108","author":"Beyar-Katz","year":"2022","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.016_bib0019","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"27","key":"10.1016\/j.jtct.2026.05.016_bib0020","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.016_bib0021","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.jtct.2026.05.016_bib0022","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2026.05.016_bib0023","doi-asserted-by":"crossref","first-page":"851.e1","DOI":"10.1016\/j.jtct.2022.09.007","article-title":"Impact of cytomegalovirus replication in patients with aggressive B cell lymphoma treated with chimeric antigen receptor T cell therapy","volume":"28","author":"M\u00e1rquez-Algaba","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"14","key":"10.1016\/j.jtct.2026.05.016_bib0024","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1182\/bloodadvances.2024012922","article-title":"Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy","volume":"8","author":"Lin","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.016_bib0025","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Jennifer","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.016_bib0026","doi-asserted-by":"crossref","first-page":"169.e1","DOI":"10.1016\/j.jtct.2021.12.014","article-title":"Risk factors for early cytomegalovirus reactivation and impact of early cytomegalovirus reactivation on clinical outcomes after T cell-replete haploidentical transplantation with post-transplantation cyclophosphamide","volume":"28","author":"Mariotti","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.016_bib0027","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10096-019-03744-3","article-title":"Age matters: older age as a risk factor for CMV reactivation in the CMV serostatus-positive kidney transplant recipient","volume":"39","author":"Hemmersbach-Miller","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:37:04Z","timestamp":1785415024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726003581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666636726003581"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.05.016","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High Incidence of Cytomegalovirus Infection in Patients Receiving Standard of Care CD19- or BCMA-Targeted CAR-T Cell Therapies for Hematologic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}